reports
WINFARM : Growth of +9.2% in Q4 2025. 2025 revenue of €146.2m, up +6.1...
WINFARM : Growth of +9.2% in Q4 2025. 2025 revenue of €146.2m, up +6.1%. PRESS RELEASE Loudéac, 29 January 2026 Growth of +9.2% in Q4 2025 2025 revenue of €146.2m, up +6.1% WINFARM (ISIN: FR0014000P11 - ticker: ALWF), the leading French player in distance-selling of products and solutions for the agricultural and livestock industry, is today publishing its revenue for the fourth quarter of 2025 and for full-year 2025. WINFARM made consolidated revenue of €35.7 million in Q4 2025, an increase of +9.2% versus Q4 2024, representing a seventh consecutive quarter of growth. This perform...
WINFARM : Croissance de +9,2% au 4 è trimestre 2025. Chiffre d’affaire...
WINFARM : Croissance de +9,2% au 4 è trimestre 2025. Chiffre d’affaires 2025 de 146,2 M€, en hausse de +6,1%. COMMUNIQUE DE PRESSE Loudéac, 29 janvier 2026 Croissance de +9,2% au 4è trimestre 2025 Chiffre d’affaires 2025 de 146,2 M€, en hausse de +6,1% WINFARM (ISIN : FR0014000P11 – mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, annonce ce jour la publication du chiffre d’affaires du 4e trimestre 2025 et en cumul sur l’exercice 2025. Au 4è trimestre 2025, WINFARM enregistre un chiffre d'affaires consolidé de 35,7 M€, en hausse de +9,2% par rapport au...
- Guy Sips
- Jacob Mekhael
- Livio Luyten
- Wim Lewi
- Jacob Mekhael
MaaT Pharma Randomises first patient in MaaT033 phase 2 trial in NSCLC
MaaT announced that the first patient has been randomised in the investigator sponsored multicenter phase 2 (IMMUNOLIFE) trial evaluating MaaT033 (microbiome therapy, oral capsule) in combination with cemiplimab (anti PD-1 antibody) in patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance to PD-1/PD-L1 blockade following antibiotic (ATB) exposure and who present ATB-induced gut dysbiosis. Primary results after 1-year follow-up post-treatment could be expected in...
WINFARM : Calendrier de communication financière 2026.
WINFARM : Calendrier de communication financière 2026. COMMUNIQUE DE PRESSE Loudéac, le 13 janvier 2026 Calendrier de communication financière 2026 WINFARM (code ISIN : FR0014000P11 - mnémonique : ALWF), 1er groupe français proposant un ensemble de prestations de conseil, de service, et de vente à distance de produits et de solutions au monde agricole et à l’élevage, publie aujourd’hui son calendrier financier pour l’exercice 2026. DATES DE PUBLICATION 2026 CHIFFRE D’AFFAIRES ANNUEL 2025 Jeudi 29 janvier 2026, après Bourse RESULTATS ANNUELS 2025 Mardi 31 mars 2026, après Bourse CHIFF...
- Jacob Mekhael
- Thibault Leneeuw
- Jacob Mekhael
MaaT Pharma Final Xervyteg phase 3 data confirm strong survival outcom...
MaaT reported the final results from the phase 3 (ARES) trial of Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD at the American Society of Hematology (ASH) conference, being held 6-9 December 2025. The final OS results from the phase 3 (ARES) trial of MaaT013 coming in at 54% at 1 year confirm the previously reported 54% probability of survival that was shared with the topline readout in January 2025. We believe this brings a significant benefit vs. the 15% 1-year OS reported...
- Guy Sips
- Jacob Mekhael
- Livio Luyten
- Wim Hoste
- Jacob Mekhael
MaaT Pharma Model update post € 9.1m capital raise
MaaT announced the completion of a capital raise of € 9.1m (at a 9% discount to closing price prior to deal announcement), and expects to use the net proceeds of € 8.7m to fund Xervyteg commercialisation preparation in Europe, advance MaaT033 development, and prepare for a pivotal US study of Xervyteg in 2026. This capital raise unlocks a € 6m EIB tranche, extending the company's cash runway to August 2026. Upon anticipated EU approval of Xervyteg in mid-2026, MaaT is eligible to receive a € 12m...
- Mathijs Geerts Danau
MaaT Pharma Launches capital increase for gross proceeds of € 9m ...
MaaT announced the launch of a capital increase through a private placement with qualified investors and retail investors. The company intends to raise € 9m, the funds will extend the runway to summer 2026 (previously February 2026). MaaT plans to use the proceeds to fund the company's development and commercialization of Xervyteg. Trading will be suspended until at least November 14 after market close. We view this raise as a positive and reiterate our BUY rating and € 17 TP.
- Hilde Van Boxstael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Wim Lewi
WINFARM : Revenue growth of +5.1% to 30 September 2025.
WINFARM : Revenue growth of +5.1% to 30 September 2025. PRESS RELEASE Loudéac, 5 November 2025 Revenue growth of +5.1% to 30 September 2025 WINFARM (ISIN: FR0014000P11 - ticker: ALWF), the leading French player in distance-selling of products and solutions for the agricultural and livestock industry, is today reporting its revenue for the third quarter of 2025 and for the first nine months of 2025. in €m, unauditedQ3 2024Q3 2025Chg. 9M 20249M 2025Chg.Farming Supplies30.131.2+3.8% 92.896.4+3.9%Farming Production4.33.9-9.9% 10.612.1+13.9%Other10.70.9+27.7% 1.72.1+17.2%TOTAL35.136.0+2.6%...
WINFARM : Croissance de +5,1% du chiffre d’affaires au 30 septembre 20...
WINFARM : Croissance de +5,1% du chiffre d’affaires au 30 septembre 2025. COMMUNIQUE DE PRESSE Loudéac, 5 novembre 2025 Croissance de +5,1% du chiffre d’affaires au 30 septembre 2025 WINFARM (ISIN : FR0014000P11 – mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, annonce ce jour la publication du chiffre d’affaires du troisième trimestre 2025 et en cumul sur les neuf premiers mois de l’exercice 2025. En M€, non auditéT3 2024T3 2025VAR 9 mois 20249 mois 2025VARAgroFourniture30,131,2+3,8% 92,896,4+3,9%AgroProduction4,33,9-9,9% 10,612,1+13,9%Autres10,70,9+27...
- Jacob Mekhael
MaaT Pharma Uneventful 3Q25 cash and revenues
MaaT reported uneventful 3Q25 cash and revenues, where its cash and cash equivalents came in at € 22.4m, providing the company with a cash runway until the end of February 2026. We note that continued growth in revenues from MaaT013's early access program (only billable in France) is a positive sign ahead of its potential EMA approval expected mid-2026. MaaT did not provide a pipeline update, though it has previously guided for results from the investigator initiated phase 2a (PICASSO) trial of ...
- Jacob Mekhael
ASH abstracts: Autolus, Galapagos, MaaT
The abstracts for presentations at the American Society of Haematology conference (ASH, 6-9 December) became available yesterday during the day (HERE). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (new data for Aucatzyl in paediatric ALL, real world data in adult ALL, amongst others), Galapagos (additional CAR-T data in r/r MCL and r/r DLBCL) and MaaT (longer follow up from ...
WINFARM : Modalités de mise à disposition du Rapport Financier Semestr...
WINFARM : Modalités de mise à disposition du Rapport Financier Semestriel 2025. COMMUNIQUE DE PRESSE Loudéac, le 28 octobre 2025 MODALITES DE MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2025 WINFARM (code ISIN : FR0014000P11 - mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, annonce que son rapport financier semestriel 2025 a été déposé auprès de l’Autorité des Marchés Financiers (AMF), le 28 octobre 2025. Ce document est disponible sur le site de la Société à l’adresse -group.com et sur le site de l’AMF (-france.org). Il est également tenu à disp...
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
MaaT Pharma Safety board recommends MaaT033 phase 2b continues as plan...
MaaT announced that the independent data safety monitoring board (DSMB) has completed the second pre-planned safety interim analysis of the ongoing randomised controlled phase 2b (PHOEBUS) trial of MaaT033 (microbiome therapy, oral capsule) in patients undergoing an allogeneic hematopoietic stem cell transplantation (allo-HSCT), and recommended that the study continue as planned. There were no safety concerns and no excessive mortality related to MaaT033 as of today. The upcoming routine DSMB re...
Very sharp increase in EBITDA, cash generation and debt reduction in H...
Very sharp increase in EBITDA, cash generation and debt reduction in H1 2025 PRESS RELEASE Loudéac, 2 October 2025 Very sharp increase in EBITDA, cash generation and debt reduction in H1 2025 Outlook for 2025: continued growth, improvement in operating profitability and debt reduction WINFARM (ISIN: FR0014000P11 - ticker: ALWF), the leading French player in distance-selling of products and solutions for the agricultural and livestock industry, is today publishing its consolidated results for the first half of 2025. At its meeting on 1 October 2025, the Board of Directors approv...
Très forte hausse de l’EBITDA, génération de cash et baisse de l’endet...
Très forte hausse de l’EBITDA, génération de cash et baisse de l’endettement au 1er semestre 2025 COMMUNIQUE DE PRESSE Loudéac, 2 octobre 2025 Très forte hausse de l’EBITDA, génération de cash et baisse de l’endettement au 1er semestre 2025 Perspectives 2025 : poursuite de la croissance, amélioration de la rentabilité opérationnelle et désendettement WINFARM (code ISIN : FR0014000P11 - mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, publie aujourd’hui ses résultats consolidés du 1er semestre 2025. Le Conseil d’administration du 1er octobre 2025 a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.